Related references
Note: Only part of the references are listed.A physiologically based in silico kinetic model predicting plasma cholesterol concentrations in humans
Niek C. A. van de Pas et al.
JOURNAL OF LIPID RESEARCH (2012)
Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?
Olivier S. Descamps et al.
ATHEROSCLEROSIS (2011)
A physiologically-based kinetic model for the prediction of plasma cholesterol concentrations in the mouse
Niek C. A. van de Pas et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2011)
A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes
Joachim Bucher et al.
BMC SYSTEMS BIOLOGY (2011)
Modelling approach to simulate reductions in LDL cholesterol levels after combined intake of statins and phytosterols/-stanols in humans
Simone R. B. M. Eussen et al.
LIPIDS IN HEALTH AND DISEASE (2011)
The role of serum non-cholesterol sterols as surrogate markers of absolute cholesterol synthesis and absorption
T. A. Miettinen et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2011)
Systematic construction of a conceptual minimal model of plasma cholesterol levels based on knockout mouse phenotypes
Niek C. A. van de Pas et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2010)
Markers of Cholesterol Absorption and Synthesis Predict the Low-density Lipoprotein Cholesterol Response to Atorvastatin
Michel R. Hoenig et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2010)
Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial
L. Jakulj et al.
JOURNAL OF LIPID RESEARCH (2010)
Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial
Nirupa R. Matthan et al.
JOURNAL OF LIPID RESEARCH (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Applicability of non-cholesterol sterols in predicting response in cholesterol metabolism to simvastatin and fluvastatin treatment among hypercholesterolemic men
M. J. Nissinen et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2010)
Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort
John F. Thompson et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2009)
Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers
Thomas M. van Himbergen et al.
JOURNAL OF LIPID RESEARCH (2009)
Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans
Takao Watanabe et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Plasma lipoproteins: genetic influences and clinical implications
Robert A. Hegele
NATURE REVIEWS GENETICS (2009)
Management of lipids in the prevention of cardiovascular events
Helene Glassbergi et al.
ANNUAL REVIEW OF MEDICINE (2008)
Pharmacogenetic Predictors of Statin-Mediated Low-Density Lipoprotein Cholesterol Reduction and Dose Response
Deepak Voora et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2008)
Inflammatory cytokines disrupt LDL-receptor feedback regulation and cause statin resistance: a comparative study in human hepatic cells and mesangial cells
Yaxi Chen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2007)
Primary prevention of cardiovascular diseases with statin therapy - A meta-analysis of randomized controlled trials
Paaladinesh Thavendiranathan et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Centering, scaling, and transformations: improving the biological information content of metabolomics data
Robert A. van den Berg et al.
BMC GENOMICS (2006)
Pharmacogenomics of cholesterol-lowering therapy
G Schmitz et al.
VASCULAR PHARMACOLOGY (2006)
New insights into the regulation of HDL metabolism and reverse cholesterol transport
GF Lewis et al.
CIRCULATION RESEARCH (2005)
Comparative effects of lipid-lowering therapies
MH Davidson et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2004)
Food-drug interaction: grapefruit juice augments drug bioavailability - mechanism, extent and relevance
A Dahan et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2004)
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvalstaltin, and pravastatin across doses (STELLAR* trial)
PH Jones et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients
TA Miettinen et al.
ATHEROSCLEROSIS (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial
R Collins et al.
LANCET (2002)
Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism
CG Hillebrant et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2002)
Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells
H Scharnagl et al.
BIOCHEMICAL PHARMACOLOGY (2001)
The Lipid Treatment Assessment Project (L-TAP) -: A multicenter survey to evaluate the percentages of dyslipidemic, patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
TA Pearson et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Share Paper
